In the News

From the MSN article by Omar Alhassan Sepsis remains one of the most urgent clinical emergencies in modern healthcare. Each hour of delayed targeted treatment significantly increases patient mortality. For decades, intensive care and emergency clinicians have struggled with the critical challenge of distinguishing sepsis from non-infectious systemic inflammation. Conventional culture tests take days, and…

Excerpt from a discussion with Tero Vesalainen from CLPMag. A recent poll highlights growing interest in host response testing for sepsis. Immunexpress CEO Rollie Carlson discusses the findings and the future of rapid diagnostics. In a recent poll conducted by Immunexpress following a Sepsis Alliance webinar, 73% of healthcare professionals and patient advocates said they believe host…

Podcast summary: Dr. Rolland “Rollie” Carlson, CEO of Immunexpress is a veteran of the molecular diagnostics space. With over 25 years of leadership across Abbott, WaferGen, Asuragen, and more, Rollie is now focused on solving one of healthcare’s most urgent crises: Sepsis. In this episode, we explore why sepsis, despite causing more than 48 million…

In case you didn’t have a chance to tune in, you can find the archived recordings here: https://webinars.liebertpub.com/e/The-State-of-Precision-Medicine-2025

Rollie’s interview with Moira Gunn of NPR Bio Tech Nation has been published. You can listen to the interview here: https://www.biotechnation.com/episodes/dr-rollie-carlson-ceo-immunexpress

“Today we have the honor of being joined by Dr Roland Carlson, who is the Chief Executive Officer of Immuneexpress which is a Seattle-based molecular diagnostic company they’re committed to improving the outcomes for patients suspected of having sepsis and their FDA-cleared SeptiCyte technology is focused on rapidly quantifying from whole blood specific molecular markers…

Immunexpress CEO Rollie Carlson recently appeared on the Mastering Medical Device podcast. Rollie Calrson is the CEO of Immunexpress, a company that is pioneering technology that can rapidly detect sepsis. Rollie contributed to the success of Abbott Laboratories for 20 years, starting off in R&D, then transitioning to leadership positions in global businesses and start-up…

Via 360Dx, ” Jan 04, 2024 | staff reporter NEW YORK – Immunexpress announced Thursday that it has secured US Food and Drug Administration 510(k) clearance for ethylenediaminetetraacetic acid (EDTA) blood-compatible cartridges for use with the firm’s SeptiCyte Rapid test to differentiate sepsis from infection-negative systemic inflammation. Read the rest here: 360Dx

Med-Tech’s Ian Bolland interviewed Rollie Carlson, CEO of Immunexpress, about the challenges of diagnosing sepsis and the technology that is being developed to tackle it.